Amneal Pharmaceuticals (AMRX) announced that three large insurance coverage accounts, the Veterans Administration, UnitedHealthcare (UNH) and CVS Health (CVS), have added Crexont extended-release capsules for the treatment of Parkinson’s disease to their national prescription drug formularies. Crexont is a prescription medication for the treatment of PD approved by the FDA in August 2024. This expanded coverage increases Crexont’s total U.S. insurance coverage from about 30% of covered lives at the end of 2024 to over 50%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals announces U.S. launch of Boruzu
- Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment
- Amneal Pharmaceuticals BLA submissions for denosumab biosimilars accepted by FDA
- Amneal Pharmaceuticals price target raised to $11 from $10 at Barclays
- Amneal Pharmaceuticals Reports Strong 2024 Financial Results